First cancer vaccine approved for women

Women now have the option of being immunized against cervical cancer following approval of Merck's Gardasil. Gardasil is a quadrivalent vaccine prepared from human papillomavirus (HPV) proteins. It provides 100% protection against HPV types 15 and 18 - the virus types that cause approximately 7...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2006-07, Vol.150 (14), p.13
Main Author: Karpa, Kelly Dowhower
Format: Magazinearticle
Language:English
Subjects:
Cancer vaccines
Cervical cancer
FDA approval
Human papillomavirus
Licensing, certification and accreditation
Pharmaceutical industry
Product development
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 14
container_start_page 13
container_title Drug Topics
container_volume 150
creator Karpa, Kelly Dowhower
description Women now have the option of being immunized against cervical cancer following approval of Merck's Gardasil. Gardasil is a quadrivalent vaccine prepared from human papillomavirus (HPV) proteins. It provides 100% protection against HPV types 15 and 18 - the virus types that cause approximately 70% of cervical cancers) and 99% protection against HPV types 6 and 11 (these types cause approximately 90% of genital warts. It is approved for use in women and girls between the agens of 9 and 25 years for the prevention of cervical cancer, genital warts and precancerous lesions.
format magazinearticle
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_reports_205014955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A167933649</galeid><sourcerecordid>A167933649</sourcerecordid><originalsourceid>FETCH-LOGICAL-g204t-d4bbc945e4dd29fe2928e6254e2acb938cd2eb6837498a437b336682532b115d3</originalsourceid><addsrcrecordid>eNptzs9LwzAUB_AgCtbp_1Aveqrkd5PjGM4JAy96Lmny2lW6pCbZ_PctzMMO4x0ePD7fL-8KFUSzulJE1NeowJjQSkoib9FdSt8YYy5FXaDn9RBTLq3xFmJ5NNYOHkozTTEcwZVdiOVv2IO_RzedGRM8_O8F-lq_fq421fbj7X213FY9xTxXjret1VwAd47qDqimCiQVHKixrWbKOgqtVKzmWhnO6pYxKRUVjLaECMcW6PHUOz_wc4CUmwhTiDk1FAtMuBZiNtXJ9GaEZvBdyNHYHjxEMwYP3TCfl0TWei7nevYvF_w8DvaDvRh4OgvswIx5l8J4yEPw6Rz-AQiYaBs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>205014955</pqid></control><display><type>magazinearticle</type><title>First cancer vaccine approved for women</title><source>Business Source Ultimate</source><creator>Karpa, Kelly Dowhower</creator><creatorcontrib>Karpa, Kelly Dowhower</creatorcontrib><description>Women now have the option of being immunized against cervical cancer following approval of Merck's Gardasil. Gardasil is a quadrivalent vaccine prepared from human papillomavirus (HPV) proteins. It provides 100% protection against HPV types 15 and 18 - the virus types that cause approximately 70% of cervical cancers) and 99% protection against HPV types 6 and 11 (these types cause approximately 90% of genital warts. It is approved for use in women and girls between the agens of 9 and 25 years for the prevention of cervical cancer, genital warts and precancerous lesions.</description><identifier>ISSN: 0012-6616</identifier><identifier>EISSN: 1937-8157</identifier><identifier>CODEN: DGTNA7</identifier><language>eng</language><publisher>Monmouth Junction: Intellisphere, LLC</publisher><subject>Cancer vaccines ; Cervical cancer ; FDA approval ; Human papillomavirus ; Licensing, certification and accreditation ; Pharmaceutical industry ; Product development ; Vaccines</subject><ispartof>Drug Topics, 2006-07, Vol.150 (14), p.13</ispartof><rights>COPYRIGHT 2006 Intellisphere, LLC</rights><rights>Copyright Advanstar Communications, Inc. Jul 24, 2006</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,780,784,791</link.rule.ids></links><search><creatorcontrib>Karpa, Kelly Dowhower</creatorcontrib><title>First cancer vaccine approved for women</title><title>Drug Topics</title><description>Women now have the option of being immunized against cervical cancer following approval of Merck's Gardasil. Gardasil is a quadrivalent vaccine prepared from human papillomavirus (HPV) proteins. It provides 100% protection against HPV types 15 and 18 - the virus types that cause approximately 70% of cervical cancers) and 99% protection against HPV types 6 and 11 (these types cause approximately 90% of genital warts. It is approved for use in women and girls between the agens of 9 and 25 years for the prevention of cervical cancer, genital warts and precancerous lesions.</description><subject>Cancer vaccines</subject><subject>Cervical cancer</subject><subject>FDA approval</subject><subject>Human papillomavirus</subject><subject>Licensing, certification and accreditation</subject><subject>Pharmaceutical industry</subject><subject>Product development</subject><subject>Vaccines</subject><issn>0012-6616</issn><issn>1937-8157</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2006</creationdate><recordtype>magazinearticle</recordtype><recordid>eNptzs9LwzAUB_AgCtbp_1Aveqrkd5PjGM4JAy96Lmny2lW6pCbZ_PctzMMO4x0ePD7fL-8KFUSzulJE1NeowJjQSkoib9FdSt8YYy5FXaDn9RBTLq3xFmJ5NNYOHkozTTEcwZVdiOVv2IO_RzedGRM8_O8F-lq_fq421fbj7X213FY9xTxXjret1VwAd47qDqimCiQVHKixrWbKOgqtVKzmWhnO6pYxKRUVjLaECMcW6PHUOz_wc4CUmwhTiDk1FAtMuBZiNtXJ9GaEZvBdyNHYHjxEMwYP3TCfl0TWei7nevYvF_w8DvaDvRh4OgvswIx5l8J4yEPw6Rz-AQiYaBs</recordid><startdate>20060724</startdate><enddate>20060724</enddate><creator>Karpa, Kelly Dowhower</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>K9.</scope><scope>U9A</scope></search><sort><creationdate>20060724</creationdate><title>First cancer vaccine approved for women</title><author>Karpa, Kelly Dowhower</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g204t-d4bbc945e4dd29fe2928e6254e2acb938cd2eb6837498a437b336682532b115d3</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Cancer vaccines</topic><topic>Cervical cancer</topic><topic>FDA approval</topic><topic>Human papillomavirus</topic><topic>Licensing, certification and accreditation</topic><topic>Pharmaceutical industry</topic><topic>Product development</topic><topic>Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Karpa, Kelly Dowhower</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Drug Topics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karpa, Kelly Dowhower</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First cancer vaccine approved for women</atitle><jtitle>Drug Topics</jtitle><date>2006-07-24</date><risdate>2006</risdate><volume>150</volume><issue>14</issue><spage>13</spage><pages>13-</pages><issn>0012-6616</issn><eissn>1937-8157</eissn><coden>DGTNA7</coden><abstract>Women now have the option of being immunized against cervical cancer following approval of Merck's Gardasil. Gardasil is a quadrivalent vaccine prepared from human papillomavirus (HPV) proteins. It provides 100% protection against HPV types 15 and 18 - the virus types that cause approximately 70% of cervical cancers) and 99% protection against HPV types 6 and 11 (these types cause approximately 90% of genital warts. It is approved for use in women and girls between the agens of 9 and 25 years for the prevention of cervical cancer, genital warts and precancerous lesions.</abstract><cop>Monmouth Junction</cop><pub>Intellisphere, LLC</pub></addata></record>
fulltext fulltext
identifier ISSN: 0012-6616
ispartof Drug Topics, 2006-07, Vol.150 (14), p.13
issn 0012-6616
1937-8157
language eng
recordid cdi_proquest_reports_205014955
source Business Source Ultimate
subjects Cancer vaccines
Cervical cancer
FDA approval
Human papillomavirus
Licensing, certification and accreditation
Pharmaceutical industry
Product development
Vaccines
title First cancer vaccine approved for women
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A53%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20cancer%20vaccine%20approved%20for%20women&rft.jtitle=Drug%20Topics&rft.au=Karpa,%20Kelly%20Dowhower&rft.date=2006-07-24&rft.volume=150&rft.issue=14&rft.spage=13&rft.pages=13-&rft.issn=0012-6616&rft.eissn=1937-8157&rft.coden=DGTNA7&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA167933649%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g204t-d4bbc945e4dd29fe2928e6254e2acb938cd2eb6837498a437b336682532b115d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=205014955&rft_id=info:pmid/&rft_galeid=A167933649&rfr_iscdi=true